Executive Vice President & Chief Scientific Officer, Research & Early Development, Novo Nordisk A/S
Professor Marcus Schindler is Executive Vice President (EVP) and Chief Scientific Officer, Research & Early Development at Novo Nordisk A/S. Marcus joined Novo Nordisk in 2018 as Senior Vice President for External Innovation & Strategy before he was appointed to lead Global Drug Discovery. Over the last 3 years he has led the transformation of drug discovery towards novel therapy areas such as Cardiovascular (CV) and Non-Alcoholic Steatohepatitis (NASH), human centric approaches, a portfolio of projects with new modes of action and the implementation of novel treatment modalities such as Stem cells and siRNA. The organization also opened to more external innovation and diversity of approach with a significant increase in partnerships, the establishment of an Innovation Hub in Boston and Transformational Research Units (TRU).
Since March 1, 2021, he leads the newly created EVP area Research and Early Development (R&ED) with accountability for driving scientific innovation to human proof-of-mechanism.
He also represents Novo Nordisk as Supervisory Board Member of Innate Pharma (France) and is Adjunct Professor of Pharmacology at the University of Gothenburg (Sweden).
Marcus has close to 20 years of experience in leadership roles in the pharmaceutical industry, working both in international large pharma and biotechnology companies including AstraZeneca (Sweden), Boehringer Ingelheim (Germany) and (OSI)Prosidion (UK).
Marcus Schindler received his PhD in Pharmacology from the University of Cambridge. He as co-/authored 50+ peer-reviewed research papers and is an inventor of 25 international patent applications.